Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Ronald W. Penczek, Chief Accounting Officer and Controller at Elevance Health, Inc. (NYSE:ELV), a prominent healthcare provider with a market capitalization of $96 billion and "GREAT" financial health according to InvestingPro, recently sold 443 shares of the company’s common stock. The transaction, executed on March 10, 2025, was completed at a price of $415.13 per share, resulting in a total sale value of $183,902. Following this transaction, Penczek holds 1,847 shares in the company. The stock, which has maintained dividend payments for 15 consecutive years and trades at a P/E ratio of 16.3, currently appears undervalued according to InvestingPro’s Fair Value model. Discover 8 more exclusive insights about ELV with InvestingPro.
In other recent news, Elevance Health has confirmed its earnings forecast for 2025, projecting adjusted earnings per share between $34.15 and $34.85. This announcement aligns with the company’s previous expectations for Medicare Advantage membership, which is anticipated to range from 2.2 million to 2.25 million members by the end of 2025. Additionally, Elevance Health is under scrutiny as part of a broader industry concern following a DOJ investigation into Medicare billing practices at UnitedHealth Group (NYSE:UNH), though no direct accusations have been made against Elevance.
Cantor Fitzgerald has maintained an Overweight rating for Elevance Health, setting a price target of $485, while highlighting the company’s exposure to Medicaid policy changes. In contrast, JPMorgan has reduced its price target for Elevance to $479, citing a mixed outlook from recent earnings reports and challenges in the Medicaid segment. However, JPMorgan notes potential growth in Elevance’s Carelon segment and anticipates margin improvements in Medicaid due to state rate updates.
The healthcare sector has seen fluctuations, with Elevance Health experiencing a 2.2% rise in stock following President Trump’s supportive comments on social programs like Medicare and Medicaid. These developments reflect a complex landscape for Elevance Health, where regulatory scrutiny, policy changes, and financial forecasts are key factors for investors to consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.